SCHEMBL3768205

SCHEMBL3768205

CC(=O)c1cnc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cn1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 11/20 0.46
ADRA1A P35348 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774207 0.85 HRH3 (0.43) HRH3NPSR1ALDH1A1MAPTMEN1
SCHEMBL3774013 0.84 HRH3 (0.66) HRH3ADRA1AALDH1A1MAPTMEN1
SCHEMBL3762752 0.83 HRH3 (0.50) HRH3NPSR1HTTALDH1A1MAPT
SCHEMBL3768152 0.82 HRH3 (0.63) HRH3ADRA1ANPSR1HTTALDH1A1
SCHEMBL3768923 0.82 PARP1 (0.44) HRH3NPSR1ALDH1A1MAPTMEN1
SCHEMBL3780579 0.81 HRH3 (0.44) HRH3NPSR1ALDH1A1MAPTMEN1
SCHEMBL3766131 0.81 HRH3 (0.46) HRH3NPSR1HTTMEN1KMT2A
SCHEMBL3771792 0.81 SMO (0.42) HRH3NPSR1HTTALDH1A1
SCHEMBL3776927 0.81 SMO (0.42) HRH3NPSR1HTTALDH1A1MAPT
SCHEMBL3776088 0.81 ALDH1A1 (0.48) HRH3ADRA1ANPSR1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885ADRA1A 365/4885NPSR1 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.